EFPIA Challenges Conclusions Of New EC Report On Drug Pricing
This article was originally published in Scrip
The European Commission may not have much of a say in drug pricing matters beyond making sure member states meet the requirements of the price transparency directive, but it certainly makes no bones about encouraging countries to act more collaboratively in dealing with the high prices of some new medicines and thereby improving access.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.